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The genetics of panic disorder
Panic disorder (PD) has a population prevalence of 3.4 to 
4.7%  and  is  the  most  common  anxiety  disorder  [1,2]. 
According to the American Psychiatric Association, PD 
is defined as an episode of abrupt, intense fear accom­
panied  by  additional  physiological  or  cognitive  symp­
toms.  Other  anxiety  disorders  and  also  mood  and 
substance­use disorders are frequently observed as co­
morbidities [3,4]. Family and twin studies have consis­
tently shown that genetic factors explain approximately 
48% of the variance in the disease [5], and segregation 
analyses support the view that the majority of PD cases 
have a complex genetic basis. This is also highlighted by 
several animal breeding experiments, which reveal that 
anxiety  or  emotional  activity  analogous  to  panic  and 
anxiety  is  controlled  by  multiple  genes,  possibly  in 
varying combinations [6]. However, the genetic archi  tec­
ture underlying PD is heterogeneous and differs between 
cases. For example, the degree of genetic complexity and 
the  pattern  of  genes  involved  might  be  different  in 
familial versus non­familial, early­ versus late­onset cases 
or  when  different  co­morbid  conditions,  gender  and 
potential intermediate or sub­phenotypes are considered.
On the molecular genetic level, linkage and candidate 
gene studies have been used for the genetic analysis of 
PD, and several potential linkage loci and tentative asso­
ciations with candidate genes have been found [7]. For 
several  reasons,  serotonergic  neurotransmission,  and 
especially  the  serotonin  transporter  gene  SLC6A4,  has 
attracted  attention  in  the  PD  research  field.  Selective 
serotonin reuptake inhibitors (SSRIs) that target SLC6A4 
are commonly used and effective treatments for PD [8]. 
In addition, mouse experiments have shown that SLC6A4 
underexpression leads to anxiety­like behavior [9], which 
would  be  in  accordance  with  human  studies  that  have 
found  decreased  SLC6A4  expression  in  brains  of  PD 
patients [10].
On the genomic level, SLC6A4 is located on chromo­
some 17q11 and consists of 15 exons. A large amount of 
genetic  variation  has  been  observed  in  SLC6A4.  An 
insertion­deletion polymorphism in the promoter region 
of  SLC6A4,  called  5­HTTLPR,  has  attracted  particular 
attention  because  it  has  been  shown  that  this  poly­
morphism  alters  gene  and  protein  expression  and  the 
low­expressing  short  variant  has  been  associated  with 
anxiety [11]. Moreover, an association has been found, in 
healthy  individuals  as  well  as  in  patients  with  major 
depression, between 5­HTTLPR and increased amygdala 
activation in response to fearful stimuli [12­14]. However, 
most PD genetic association studies have failed to find an 
association  between  5­HTTLPR  variants  or  amygdala 
activation and panic disorder [15­17].
The role of a 3’ SLC6A4 polymorphism in PD
A recently published study by Gyawali et al. [18] reports 
evidence that SLC6A4 might contribute to the develop­
ment of PD by a mutation other than 5­HTTLPR. Their 
study [18] followed findings [19] of an association between 
PD  and  polymorphisms  located  in  the  3’  untranslated 
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© 2010 BioMed Central Ltdregion  (UTR)  of  SLC6A4.  None  of  these  3’  UTR­
associated  variants  showed  linkage  disequilibrium  to 
5­HTTLPR, suggesting an independent SLC6A4 locus at 
the 3’ end of the gene. It is known that the SLC6A4 3’ 
UTR is expressed in two alternative forms that differ by 
the presence or absence of a 123­bp element [20] and the 
more 3’ (distal) form contains an additional polyadeny­
lation signal. Gyawali et al. [18] hypothesized that one 
particular SNP ­ rs3813034 ­ located within this signal 
would alter the usage of this form relative to the more 5’ 
(proximal) form. To test this hypothesis, the authors [18] 
analyzed  65  post  mortem  human  brain  samples  and 
found  that  in  brains  expressing  one  of  the  rs3813034 
alleles ­ coding for G ­ the relative expression of the distal 
to  the  proximal  SLC6A4  form  was  significantly  lower 
than that of brain samples carrying the alternative (T) 
allele. The same effect was seen in 71 human lymphoblast 
cultures.  The  authors  [18]  also  found  evidence  that 
gender­specific effects contributed to the observed allele­
specific  expression  differences.  The  distal  form  of 
SLC6A4 was less expressed in brain samples from females 
than  in  those  from  males.  To  ensure  that  the  gender­
specific association is a true positive finding, the authors 
[18] analyzed both expressed SLC6A4 isoforms in brains 
of  male  and  female  mice.  In  this  dataset  they  also 
observed  gender  differences  similar  to  those  seen  in 
humans, with a lower expression of the distal SLC6A4 
isoform in female mouse brains.
Gyawali et al. [18] also examined whether rs3813034 
is  itself  the  variant  causing  the  observed  SLC6A4­
expres  sion  differences.  Using  a  functional  approach, 
they  cloned  both  forms  of  the  3’  SLC6A4  UTR  into 
plasmids; one construct encoded allele G and the other 
one allele T of rs3813034, and the remaining sequence 
was  identical.  The  relative  expression  of  the  two 
polyadenylation  forms  was  then  quantified  and  the 
authors  [18]  observed  that  the  G  allele  of  rs3813034 
caused  significantly  lower  usage  of  the  distal  poly­
adenylation form than allele T.
Finally, rs3813034 was tested for PD association in a 
large case­control study (n = 307 PD patients and 544 
controls)  [18].  The  G  allele  ­  associated  with  lower 
expres  sion  of  the  distal  SLC6A4  isoform  ­  was  signifi­
cantly more frequent in patients (51%) than in controls 
(44%; P = 0.002) and thereby found to be the PD risk 
allele. This effect became stronger when the participants 
were stratified by gender. The risk allele was significantly 
more frequent in female PD patients (51%) than female 
controls (42%) (P = 0.003), whereas no G­allele associa­
tion was observed in males (P = 0.233) [18]. The finding 
was in accordance with the expression experiments, in 
which lower expression levels of the distal SLC6A4 form 
were  observed  in  female  brain  samples  from  both 
humans and mice.
Conclusions and perspectives
These results are encouraging and are shedding new light 
on  the  role  of  SLC6A4  variation  in  panic  disorder. 
Nevertheless, some questions remain. In particular, it has 
yet to be shown how a lower expression level of the distal 
SLC6A4  isoform  affects  protein  function  quantitatively 
and qualitatively, for example in a gender­ and/or cell­
type­specific  manner.  This  is  especially  important 
because  the  short  5­HTTLPR,  with  an  obvious  lower 
protein expression, has consistently been shown not to be 
associated with panic disorder. Given that SLC6A4 has 
never been tested systematically for association and the 
gene might harbor several potential risk variants, possible 
explanations for the discrepant findings may be that the 
interaction  between  different  polymorphisms  has  not 
been  controlled  for  in  previous  studies  or  that  it  has 
gender­ or cell­ type­specific consequences. Studies on 
large  PD  datasets  with  sufficient  marker  coverage  for 
extensive  haplotype  analyses  and  additional  functional 
studies are now required.
Although these two recent reports [18,19] are evidence 
that  candidate­gene  studies  can  still  provide  some 
surprises,  this  approach  has  obvious  limitations.  In 
contrast, as with other disorders, modern genome­wide 
association studies of sufficiently large sample size will 
most probably lead to the identification of novel PD risk 
genes  in  the  coming  years  and  will  contribute  to  our 
understanding of the underlying neurobiology of anxiety­
related disorders and behaviors [21,22]. This will increase 
our  understanding  of  anxiety  disorders  and  aid  the 
development of better prevention strategies.
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